Answers are grounded in this paper and cite their sources.
Randomized trial shows rapid improvement in disease activity in dermatomyositis with dazukibart treatment, highlighting its potential benefits.
Purpose: Interferon-β (IFNβ) dysregulation contributes to dermatomyositis (DM) pathogenesis. In a previously published phase 2 study, 12-week treatment with dazukibart, an anti-IFNβ monoclonal antibody, reduced disease activity in moderate-to-severe DM. This prespecified secondary analysis evaluated the rapidity of onset of efficacy of dazukibart in DM at time points before Week 12, which may inform treatment decisions. Patients and Methods: This is a secondary analysis of a double-blind, randomized, placebo-controlled phase 2 study (NCT03181893). Adults with skin-predominant (SP) or muscle-predominant (MP) DM received placebo or dazukibart (150 mg/600 mg) at baseline and every 4 weeks. Efficacy outcomes assessed at Weeks 1, 4, and 8 included: SP cohort–change from baseline (CFB) in Cutaneous Dermatomyositis Disease Area and Severity Index activity (CDASI-A), 5D-itch, and Dermatology Quality of Life Index (DLQI) and proportion of patients achieving ≥ 40% decrease in CDASI-A; MP cohort–Mean Total Improvement Score (TIS), CFB in myositis core set measures, and TIS response. Results: In SP cohort (n=57), statistically significant improvement was observed with dazukibart in mean CFB (placebo-adjusted difference) CDASI-A (Week 4; 150 mg: − 10.5 [p=0.0006]; 600 mg: − 9.7 [p=0.0004]), 5D-itch (Week 1; 600 mg: − 2.0 [p=0.0359]), and DLQI (Week 4; 150 mg: − 2.8 [p=0.0249]; 600 mg: − 2.7 [p=0.0160]). CDASI-A score decreased by ≥ 40% in 53.3% (dazukibart 150 mg), 42.9% (dazukibart 600 mg), and 7.7% (placebo) patients at Week 4. In MP cohort (n=18), numerical improvements (sample size not powered to detect statistical significance) with dazukibart 600 mg vs placebo in mean TIS (Week 4) and statistically significant improvements in mean CFB creatine kinase levels (Week 4; p=0.0445) and Patient Global Assessment (Week 8; p=0.0470) were observed. At Week 4, 77.8% and 22.2% (dazukibart 600 mg) vs 66.7% and 0 (placebo) patients achieved minimal and major improvement, respectively. Conclusion: Dazukibart induced rapid improvement in key skin- and muscle-related efficacy outcomes of disease activity in patients with DM. The small sample size of the MP cohort warrants a well-powered Phase 3 study to confirm these Phase 2 proof-of-concept results. Trial Registration: NCT03181893 Plain Language Summary: Dermatomyositis (DM) is an autoimmune disease that affects skin and muscles. Since currently available treatments have limited efficacy, more effective options are needed. Results from a phase 2 study showed improvement with 12-week treatment with dazukibart, a drug targeting a key immune system regulator called interferon beta (INFβ). In this study, we report the onset of response to dazukibart. In patients with predominantly skin disease (skin cohort), we measured improvement in skin symptoms using Cutaneous Dermatomyositis Disease Area and Severity Index-Activity scores (CDASI-A), itch-relief using 5D-itch scores, and quality of life (QoL) using Dermatology QoL Index scores. We calculated the proportion of patients achieving at least 40% improvement in CDASI-A, indicating an improvement in patient’s QoL. In patients with predominantly muscle disease (muscle cohort), we measured improvement in muscle symptoms using Total Improvement Score (TIS) and assessed the proportion of patients achieving minimal, moderate, or major improvement in TIS. In the skin cohort, dazukibart treatment resulted in significant improvement as early as Week 4 in skin symptoms and QoL and Week 1 in itch relief. At Week 4, improvement in skin symptoms was associated with improvement in QoL (at least 40% improvement in CDASI-A) in more than half of patients treated. In the muscle cohort, dazukibart led to improvement in TIS as early as Week 4 and more than 75% of patients achieved at least minimal improvement with dazukibart. Overall, dazukibart treatment resulted in rapid improvement in important skin and muscle symptoms in patients with DM.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: